SEC-sourced researchBeta
TNGX
Tango Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001819133
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 5, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 36,527,000.0000 | Mar 5, 2026 |
| December 2024 | 42,069,000.0000 | Mar 5, 2026 |
| December 2025 | 62,384,000.0000 | Mar 5, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 62,384,000.0000 | -101,594,000.0000 | -138,886,000.0000 | 398,690,000.0000 | 52,511,000.0000 | Mar 5, 2026 |
| December 2024 | 42,069,000.0000 | -130,302,000.0000 | -131,501,000.0000 | 316,492,000.0000 | 116,975,000.0000 | Mar 5, 2026 |
| December 2023 | 36,527,000.0000 | -101,744,000.0000 | -117,982,000.0000 | — | — | Mar 5, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $62.38M | December 2025 | Mar 5, 2026 | 10-K |
| Previous period revenueRevenues | $42.07M | December 2024 | Mar 5, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$101.59M | December 2025 | Mar 5, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$138.89M | December 2025 | Mar 5, 2026 | 10-K |
| Total assetsAssets | $398.69M | December 2025 | Mar 5, 2026 | 10-K |
| Total liabilitiesLiabilities | $52.51M | December 2025 | Mar 5, 2026 | 10-K |